Tiludronate: Difference between revisions
m Protected "Tiludronate": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
| Line 1: | Line 1: | ||
{{drugbox | {{drugbox | ||
| Line 35: | Line 35: | ||
* [http://products.sanofi-aventis.us/skelid/skelid.html Prescribing information for Skelid] | * [http://products.sanofi-aventis.us/skelid/skelid.html Prescribing information for Skelid] | ||
* [http://www.rxlist.com/cgi/generic2/tiludronate.htm RxList page] | * [http://www.rxlist.com/cgi/generic2/tiludronate.htm RxList page] | ||
[[Category:Bisphosphonates]] | [[Category:Bisphosphonates]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
Revision as of 16:56, 20 August 2012
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C7H9ClO6P2S |
| Molar mass | 318.609 g/mol |
|
WikiDoc Resources for Tiludronate |
|
Articles |
|---|
|
Most recent articles on Tiludronate Most cited articles on Tiludronate |
|
Media |
|
Powerpoint slides on Tiludronate |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Tiludronate at Clinical Trials.gov Clinical Trials on Tiludronate at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Tiludronate
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Tiludronate Discussion groups on Tiludronate Patient Handouts on Tiludronate Directions to Hospitals Treating Tiludronate Risk calculators and risk factors for Tiludronate
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Tiludronate |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Tiludronic acid (INN) or Tiludronate (USAN), marketed as under the brand name Skelid®, is a bisphosphonate used to treat Paget's disease.
Administration
Tiludronic acid is administered orally. The recommended dose is a single 400-mg daily oral dose, taken with 6 to 8 ounces of plain water only, should be administered for a period of 3 months. Beverages other than plain water (including mineral water), food (see below), and some medications are likely to reduce the tiludronic acid's absorption.
External links
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Bisphosphonates
- Endocrinology